Hong Kong Healthcare Stocks Surge; Everest Medicines Up Over 48%, CanSino Biologics Up Over 46%
Hong Kong-listed pharmaceutical and biotech stocks extended their rally, with multiple names posting sharp gains during the trading session. As of the latest data, Everest Medicines surged more than 48%, CanSino Biologics climbed over 46%, and Aim Vaccine advanced over 26%. China Biopharmaceutical rose over 17%, CSPC Pharmaceutical gained over 14%, and Fosun Pharma added over 7%. The broad-based advance underscored robust investor appetite for healthcare names in the Hong Kong market.
Hong Kong-listed pharmaceutical and biotech stocks continued to climb, with multiple names recording significant gains. As of the trading session, Everest Medicines rose more than 48%, CanSino Biologics gained over 46%, Aim Vaccine advanced over 26%, Sino Biopharmaceutical increased over 17%, CSPC Pharmaceutical rose over 14%, and Fosun Pharma added over 7%.